Arrowhead Research
ARWR

$28.19

2.59%

Market Cap: 3.5B

About: Arrowhead Pharmaceuticals Inc is an American biotechnology company. Its main target is the development of medicine to treat diseases with a genetic origin, characterized by the overproduction of one or more proteins. Its medical solutions are aimed at the genes that trigger the diseases. Its portfolio includes drugs targeting hepatitis B, Alpha-1 Antitrypsin Deficiency, thrombosis and angioedema, clear-cell and renal cell carcinoma, and cardiovascular disease.

Employees: 525

Healthcare Pharmaceutical Preparations

0

Funds holding %

of 6,702 funds

0

Analysts bullish %

of 15 analysts

0

News positive %

of 3 articles

Fund manager confidence

Based on 2024 Q1 SEC filings by fund managers ($100M+ AUM)

123% more call options, than puts

Call options by funds: $28.4M | Put options by funds: $12.8M

49% more repeat investments, than reductions

Existing positions increased: 106 | Existing positions reduced: 71

14% more capital invested

Capital invested by funds: $2.37B [Q4 2023] → $2.71B (+$343M) [Q1 2024]

4.5% more ownership

Funds ownership: 72.14% [Q4 2023] → 76.63% (+4.5%) [Q1 2024]

3% more first-time investments, than exits

New positions opened: 36 | Existing positions closed: 35

0% more funds holding

Funds holding: 264 [Q4 2023] → 265 (+1) [Q1 2024]

25% less funds holding in top 10

Funds holding in top 10: 4 [Q4 2023] → 3 (-1) [Q1 2024]

See Fund Rankings

Research analyst outlook

15 Wall Street Analysts provided 1 year price forecasts over the past 6 months

Low target

$27

4%

downside

Avg. target

$60

112%

upside

High target

$90

219%

upside

15 analyst ratings

11 positive

73%

4 neutral

27%

0 negative

0%

HC Wainwright & Co. Patrick Trucchio	113%upside $60	Buy Reiterated	23 Jul 2024
Chardan Capital Keay Nakae	113%upside $60	Buy Maintained	17 Jul 2024
HC Wainwright & Co. Patrick Trucchio	113%upside $60	Buy Maintained	5 Jul 2024
Chardan Capital Keay Nakae	113%upside $60	Buy Maintained	26 Jun 2024
HC Wainwright & Co. Patrick Trucchio	219%upside $90	Buy Reiterated	11 Jun 2024

See Analyst Rankings

Financial journalist opinion

Based on 3 articles about ARWR published over the past 30 days

Arrowhead Pharmaceutical: Driving To Commercialization

Arrowhead Pharmaceuticals has a promising pipeline of drug candidates based on RNAi methodology. It has developed a tighter focus to push its most promising cardiometabolic drug (Plozasiran) toward FDA approval and commercialization. The new focus is manifested in practical ways that enhance the prospects of commercialization.

Arrowhead Pharmaceutical: Driving To Commercialization

Arrowhead Pharmaceuticals to Webcast Fiscal 2024 Third Quarter Results

PASADENA, Calif.--(BUSINESS WIRE)---- $arwr--Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced that it will host a webcast and conference call on August 8, 2024, at 4:30 p.m. ET to discuss its financial results for the fiscal third quarter ended June 30, 2024. Webcast and Conference Call and Details Investors may access a live audio webcast on the Company's website at http://ir.arrowheadpharma.com/events.cfm. A replay of the webcast will be available approximately two hours after the conclus.

Arrowhead Pharmaceuticals to Webcast Fiscal 2024 Third Quarter Results

Have 20 Bucks? 7 Low-Priced Stocks That Could Double by 2025

Low-priced stocks to buy with the potential to double within the next year or so have inherent appeal for investors. Individual shares are affordable making it relatively easy to establish a stake.

Have 20 Bucks? 7 Low-Priced Stocks That Could Double by 2025

Canva Upskills 70 Million Educators and Students Globally with New Teacher Certification Course

SYDNEY--(BUSINESS WIRE)--Canva, the world's leading visual communication platform, continues to experience significant growth in its global K-12 and higher education user base, adding 40 million users in the past year alone. With 70 million teachers and students now onboard, comprising nearly half of Canva's total users, this growth is driven by AI integration and visual communication adoption across prominent institutions like the University of California, New York City Public Schools, and the.

Canva Upskills 70 Million Educators and Students Globally with New Teacher Certification Course

Arrowhead Pharmaceuticals to Advance RNAi-based Plozasiran into Phase 3 CAPITAN Cardiovascular Outcomes Trial

PASADENA, Calif.--(BUSINESS WIRE)---- $arwr--Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced plans to advance investigational plozasiran into a Phase 3 cardiovascular outcomes trial called CAPITAN. This comes after promising results were recently announced from multiple clinical trials in three distinct patient populations, including the pivotal Phase 3 PALISADE study in patients with genetically confirmed or clinically diagnosed familial chylomicronemia syndrome (FCS), the Phase 2 SHASTA-.

Arrowhead Pharmaceuticals to Advance RNAi-based Plozasiran into Phase 3 CAPITAN Cardiovascular Outcomes Trial

Arrowhead Pharmaceuticals Presents Preclinical Data on New RNAi-Based Obesity Program ARO-INHBE

PASADENA, Calif.--(BUSINESS WIRE)---- $arwr--Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced that preclinical data on ARO-INHBE, an investigational RNAi-based medicine for the treatment of obesity and metabolic diseases, were presented at the American Diabetes Association (ADA) 84th Scientific Sessions, which were held June 21-24, in Orlando, FL, and virtually. The preclinical results demonstrate that ARO-INHBE substantially silenced hepatic expression of the INHBE gene, which has been ide.

Arrowhead Pharmaceuticals Presents Preclinical Data on New RNAi-Based Obesity Program ARO-INHBE

5 Biotech Stocks With Key Catalysts This Week: Merck, Intellia, Verona, And More

Biotech stocks are high-risk, high-return opportunities that are under the mercy of several make-or-break catalysts, most of which are binary events. It pays to remain cognizant of the timing of these catalysts and which way they will likely pan out.

5 Biotech Stocks With Key Catalysts This Week: Merck, Intellia, Verona, And More

Arrowhead Pharmaceuticals Reports Successful Topline Results for Plozasiran from the Pivotal Phase 3 PALISADE Study in Patients with Familial Chylomicronemia Syndrome

PASADENA, Calif.--(BUSINESS WIRE)---- $arwr--Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced topline results from the pivotal Phase 3 PALISADE study of investigational plozasiran in patients with genetically confirmed or clinically diagnosed familial chylomicronemia syndrome (FCS), a severe genetic disease with significant unmet need and no FDA approved therapies. PALISADE successfully met the primary endpoint of lowering triglycerides and met all key secondary endpoints, including reducin.

Arrowhead Pharmaceuticals Reports Successful Topline Results for Plozasiran from the Pivotal Phase 3 PALISADE Study in Patients with Familial Chylomicronemia Syndrome

Arrowhead Pharmaceuticals to Participate in Upcoming June 2024 Conferences

PASADENA, Calif.--(BUSINESS WIRE)---- $arwr--Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced that it is scheduled to participate in the following upcoming events: 16th European Glaucoma Society (EGS) Congress – June 1-4, 2024 Title: Development and Characterization of Trabecular Meshwork Targeted RNAi Molecule Platform via Intracameral Administration for Glaucoma Date/Time: June 2, 2024, 10:30 a.m. IST Session: Poster Section Jefferies Global Healthcare Conference – June 5-6, 2024 Type: Fi.

Arrowhead Pharmaceuticals to Participate in Upcoming June 2024 Conferences

Arrowhead Pharmaceuticals Presents New Phase 2 Data of Zodasiran in Patients with Mixed Hyperlipidemia

PASADENA, Calif.--(BUSINESS WIRE)---- $arwr--Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced results from the Phase 2b double blind, randomized ARCHES-2 study of investigational zodasiran (formerly ARO-ANG3) in patients with mixed hyperlipidemia. Zodasiran was associated with robust and durable reductions in triglycerides, triglyceride rich lipoprotein remnants, and total atherogenic lipoproteins, including LDL-C. These data were presented in a late-breaking oral presentation today at the.

Arrowhead Pharmaceuticals Presents New Phase 2 Data of Zodasiran in Patients with Mixed Hyperlipidemia

See News Rankings